LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.01
+1.94%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- -$2.06
- Revenue estimate
- $3.8K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$1.92
- EPS estimate
- -$1.90
- Revenue actual
- $4.0K
- Revenue estimate
- $3.6K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -46.3%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $41
- PT range
- $36 – $44
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$1.90 | -$1.92 | Miss -1.05% | $4.0K |
| May 6, 2026 | -$2.78 | -$1.10 | Beat 60.43% | $2.0K |
| Mar 12, 2026 | -$2.23 | -$8.23 | Miss -268.85% | $6.0K |
| Nov 12, 2025 | -$2.81 | -$2.13 | Beat 24.20% | $15.0K |
| Aug 12, 2025 | -$3.80 | -$2.89 | Beat 23.95% | $8.0K |
| Mar 11, 2025 | -$0.18 | -$0.72 | Miss -300.00% | $11.0K |
| Nov 7, 2024 | -$0.20 | -$0.17 | Beat 15.00% | $34.0K |
| Feb 28, 2024 | -$0.21 | -$0.20 | Beat 4.76% | $13.0K |
| May 4, 2023 | -$0.28 | -$0.27 | Beat 3.57% | $65.0K |
| Feb 28, 2023 | -$0.31 | -$0.03 | Beat 90.32% | — |
| Aug 4, 2022 | -$0.31 | -$0.15 | Beat 51.61% | $35.7M |
| Nov 12, 2021 | -$0.27 | -$0.20 | Beat 25.93% | $2.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026